对于一家成立仅四年的biotech企业而言，要想获得资本的青睐，离不开创新产品的加持。经过数十年的 发展，小核酸药物的药物设计和递送技术日益成熟，经历了从概念验证到人体临床试验的验证过程，其 适应证范围也从罕见病逐渐扩展到常见病领域。 在创新药资本寒冬中，一家成立仅四年的中国生物技术公司凭借三款临床阶段的小核酸药物，逆势完成 近5000万美元融资，专注于心血管代谢疾病市场，特别是在心血管慢病管理领域，这一领域在近两年成 为投资者关注的热点。 近日，靖因药业宣布成功完成近5000万美元B2轮融资，以加速其心血管代谢疾病的新型小干扰 RNA(siRNA)疗法的临床开发，并持续创新其下一代RNA递送技术。本轮融资由全球知名产业投资机构 领投，博远资本与现有投资者奥博资本，泓元资本和汉康资本共同参与。靖因药业累计融资已达1.5亿 美元，这一成绩在2025年上半年中国创新药公司融资普遍活跃的背景下显得尤为突出。 靖因药业的成就远不止于此。在成功融资后不久，该公司即宣布与CRISPR Therapeutics达成战略合作， 双方将共同开发并商业化新一代长效凝血因子XI（FXI）靶向小干扰RNA（siRNA）疗法SRSD1 ...

这里是《21健讯Daily》，欢迎与21世纪经济报道新健康团队共同关注医药健康行业最新事件！ 政策动向 中疾控专家：新冠感染的临床严重性未发生显著变化 在国家卫生健康委5月20日举行的新闻发布会上，中国疾控中心研究员安志杰表示，近期部分国家和地 区新冠疫情呈小幅上升趋势，但疾病的临床严重性没有发生显著变化。预防呼吸道传染病，在日常生活 中要保持良好个人卫生习惯，勤洗手，多通风；低龄儿童、老人及慢性病患者等免疫力较弱人群，建议 接种预防呼吸道传染病的相关疫苗。 药械审批 常山药那屈肝素钙注射液获得白俄罗斯药品注册证书 5月20日，步长制药（603858）公告，公司控股子公司浙江天元拟与辅必成(上海)医药科技有限公司就 MF59乳佐剂进行委托研发合作并签署委托研发协议。步长制药同日公告，为大力发展和整合公司大健 康产业，公司拟将持有的9家控股子公司(宁波步长贸易、山东步长药妆、山东步长鼎晟、山东步长传 方、山东步长优品、济南步长驰骋、济南步长财淦、济南步长瀛玺、济南步长众福)各1%股权转让给谢 继辉。谢继辉现任公司事业十七部总经理。 行业大事 上海医药利伐沙班片获得美国FDA批准文号 5月20日，上海医药（601 ...

Core Insights - CRISPR Therapeutics has entered a collaboration with Sirius Therapeutics to develop and commercialize novel siRNA therapies, specifically targeting thromboembolic disorders [1][3] - The lead candidate from this partnership, SRSD107, has shown promising results in early studies, indicating potential as a best-in-class therapy for thromboembolism [5][6] Financial Terms of the Collaboration - CRISPR Therapeutics will make an upfront cash payment of $25 million and $70 million in equity to Sirius Therapeutics, with both companies sharing development costs and profits equally [3][4] - CRISPR will handle commercialization in the U.S., while Sirius will lead in Greater China [3] Development Status of SRSD107 - Phase I studies have demonstrated over 93% peak reductions in FXI levels and activity, with a significant increase in activated partial thromboplastin time [5] - A Phase II study has been initiated to evaluate the safety and efficacy of SRSD107 for preventing venous thromboembolism in patients undergoing total knee arthroplasty [6] Recent Achievements - CRISPR Therapeutics, in partnership with Vertex Pharmaceuticals, received approval for Casgevy, a CRISPR/Cas9 gene-edited therapy for sickle cell disease and transfusion-dependent beta thalassemia, marking a significant milestone in medical science [8] - Vertex leads the global development and commercialization of Casgevy, sharing costs and profits with CRISPR in a 60:40 ratio [9]

Core Insights - CRISPR Therapeutics and Sirius Therapeutics have formed a strategic partnership to co-develop and commercialize SRSD107, a long-acting Factor XI (FXI) small interfering RNA (siRNA) for thromboembolic disorders [1][2] - SRSD107 has shown promising results in Phase 1 clinical trials, achieving over 93% reduction in FXI activity and more than twofold increase in activated partial thromboplastin time (aPTT), with effects lasting up to 6 months post-dosing [1][3] - The collaboration includes an upfront payment of $25 million in cash and $70 million in equity from CRISPR to Sirius, with a 50-50 cost and profit-sharing structure for SRSD107 [1][8] Company Overview - CRISPR Therapeutics is focused on creating transformative gene-based medicines and has a diverse portfolio across various disease areas, including cardiovascular diseases [10] - Sirius Therapeutics is a clinical-stage biotech company developing innovative siRNA therapies, with SRSD107 being its most advanced product targeting thromboembolic disorders [17][18] Clinical Development - The clinical program for SRSD107 includes two Phase 1 trials demonstrating safety and robust pharmacodynamic effects, with a Phase 2 trial planned to evaluate its efficacy in preventing venous thromboembolism (VTE) in total knee arthroplasty patients [3][7] - SRSD107 is designed to selectively inhibit FXI, aiming to reduce thrombotic events while minimizing bleeding risks, offering a differentiated approach compared to existing therapies [2][16] Market Potential - Thromboembolic disorders are a significant global health issue, affecting millions and representing a substantial unmet medical need [2][15] - The addressable patient population for SRSD107 includes those with atrial fibrillation, venous thromboembolism, cancer-associated thrombosis, and other conditions where existing therapies pose bleeding risks [2][3]

Financing Overview - A total of 11 financing events occurred in Shanghai this week, with 9 disclosing amounts totaling approximately 1.98 billion yuan [5][8] - The majority of financing events were concentrated in the Pudong New Area and Songjiang District, each with 2 events, while other areas had 1 event each [5] - Angel round financing was the most common, with 5 events, followed by 2 events each in Series B and strategic financing [8] Company Financing Dynamics - Xiangdao Travel announced the completion of over 1.3 billion yuan in Series C financing, aimed at expanding its market presence and enhancing its service offerings [14][15] - Jingyin Pharmaceutical completed nearly 50 million USD in B+ round financing, which will be used to advance its clinical pipeline and product development [16][18] - Pait Fresh Life secured 25 million USD in angel round financing to enhance its supply chain and product innovation in the pet food sector [19][20] - Kaan Chuang Neng completed several million yuan in Pre-A+ round financing, focusing on the development of hydrogen liquefaction systems [21][22] - Qianjue Robotics raised several million yuan in angel round financing to accelerate technology development and product iteration [23][24] - Aokun Technology completed several million yuan in angel round financing, which will be used for aviation measurement and control product development [25][26] - Baiyi Yuan Biotechnology received several million yuan in strategic financing from Kangzhe Pharmaceutical to support product development and market expansion [27][28] Industry Focus - The advanced manufacturing sector saw 3 financing events this week, focusing on aerospace, sensors, and communication technologies [29] - The Shanghai Institute of Microsystem and Information Technology made significant progress in developing high-performance MEMS fast-response mirrors for satellite laser communication [29][30] - Shanghai is committed to enhancing its manufacturing capabilities through policies aimed at supporting enterprise development and achieving high-quality growth in the manufacturing sector [30]